Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 144

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 144
---
anticipated clinical trials or trials that are larger or more complex than anticipated; 

•competition from existing and potential future products that compete with our product candidates and any of our future product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners; 

•any delays in regulatory review or approval of our product candidates; 

•the level of demand for our future product candidates, if approved, which may fluctuate significantly and be difficult to predict; 

•the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates; 

•our ability to commercialize our product candidates, if approved, inside and outside of the United States, either independently or working with third parties; 

•our ability to establish and maintain future collaborations, licensing or other arrangements; 

•our ability to adequately support future growth; 

•potential unforeseen business disruptions that increase our costs or expenses; 

•future accounting pronouncements or changes in our accounting policies; and 

•the changing and volatile global economic and political environment.

 87

The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.